...
首页> 外文期刊>Atherosclerosis >The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event
【24h】

The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event

机译:用于晚期糖糖末端产物(SRAGE)的可溶性受体具有双相依赖性与急性冠状动脉事件后残留心血管风险的关联

获取原文
获取原文并翻译 | 示例

摘要

Background and aims: The pro-inflammatory alarmin S100A12 (EN-RAGE) and the soluble form of its receptor, the receptor for advanced glycation endproducts (sRAGE), have diverging roles in cardiovascular disease. In experimental studies, S100A12 promoted atherosclerosis while sRAGE treatment was anti-atherogenic and reduced myocardial infarction size by scavenging RAGE ligands. Here, we aimed to explore the links between S100A12, sRAGE, and long-term prognosis after an acute coronary syndrome (ACS).
机译:背景和目的:促炎报警S100A12(en-RAGE)和其受体的可溶性形式,用于先进的糖糖型封端(SRAGE),具有伴随心血管疾病的作用。 在实验研究中,S100A12促进了动脉粥样硬化,而SRAGE治疗是通过清除RAGE配体的抗动脉粥样硬化和减少心肌梗死大小。 在这里,我们旨在探讨急性冠状动脉综合征(ACS)后S100A12,SRAGE和长期预后的链接。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号